首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Dynamic contrast enhanced MRI detects changes in vascular transport rate constants following treatment with thermally-sensitive liposomal doxorubicin
【24h】

Dynamic contrast enhanced MRI detects changes in vascular transport rate constants following treatment with thermally-sensitive liposomal doxorubicin

机译:动态对比增强MRI检测用热敏脂质体DOXORUBIN治疗后血管传输速率常数的变化

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Temperature-sensitive liposomal formulations of chemotherapeutics, such as doxorubicin, can achieve locally high drug concentrations within a tumor and tumor vasculature while maintaining low systemic toxicity. Further, doxorubicin delivery by temperature-sensitive liposomes can reliably cure local cancer in mouse models. Histological sections of treated tumors have detected red blood cell extravasation within tumors treated with temperature-sensitive doxorubicin and ultrasound hyperthermia. We hypothesize that the local release of drug into the tumor vasculature and resulting high drug concentration can alter vascular transport rate constants along with having direct tumoricidal effects. Dynamic contrast enhanced MRI (DCE-MRI) coupled with a pharmacokinetic model can detect and quantify changes in such vascular transport rate constants. Here, we set out to determine whether changes in rate constants resulting from intravascular drug release were detectable by MRI. We found that the accumulation of gadoteridol was enhanced in tumors treated with temperature-sensitive liposomal doxorubicin and ultrasound hyperthermia. While the initial uptake rate of the small molecule tracer was slower (k(1) = 0.0478 +/- 0.011 s(-1) versus 0.116 +/- 0.047 s(-1)) in treated compared to untreated tumors, the tracer was retained after treatment due to a larger reduction in the rate of clearance (k(2) = 0.291 +/- 0.030 s(-1) versus 0.747 +/- 0.24 s(-1)). While DCE-MRI assesses a combination of blood flow and permeability, ultrasound imaging of microvascular flow rate is sensitive only to changes in vascular flow rate; based on this technique, blood flow was not significantly altered 30 min after treatment. In summary, DCE-MRI provides a means to detect changes that are associated with treatment by thermally-activated particles and such changes can be exploited to enhance local delivery.
机译:温度敏感的化学治疗剂(如多柔比星)的脂质体配方可以在肿瘤和肿瘤脉管系统内达到局部高的药物浓度,同时保持低系统性毒性。此外,通过温度敏感脂质体递送的多柔比星可可靠地治愈小鼠模型中的局部癌症。治疗肿瘤的组织学部分检测到用温度敏感的多柔比星和超声热疗治疗的肿瘤内的红细胞外渗。我们假设药物局部释放到肿瘤脉管系统中并产生高药物浓度可以改变血管运输速率常数以及具有直接琼脂作用。与药代动力学模型偶联的动态对比增强MRI(DCE-MRI)可以检测和量化这种血管运输速率常数的变化。在这里,我们开始确定由MRI检测到血管内药物释放引起的速率常数的变化。我们发现,用温度敏感脂质体DOXORUBICIN和超声热疗治疗的肿瘤中增强了GDODOTERIDOL的积累。虽然小分子示踪剂的初始摄取率较慢(K(1)= 0.0478 +/- 0.011s(-1)与0.116 +/- 0.047 s(-1))与未处理的肿瘤相比,但是示踪剂是治疗后保留由于间隙率较大(K(2)= 0.291 +/- 0.030S(-1)对0.747 +/- 0.24 s(-1))。虽然DCE-MRI评估了血流和渗透性的组合,但微血管流量的超声成像仅敏感,仅敏感到血管流速的变化;基于这种技术,处理后30分钟没有显着改变血流量。总之,DCE-MRI提供了检测与通过热活化颗粒治疗相关的变化的方法,并且可以利用这种变化来增强局部递送。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号